NCT00235573View on ClinicalTrials.gov

Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Disorder of Vitamin B12
Interventions
DIETARY_SUPPLEMENT

Vitamin B12

After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.

Trial Locations (1)

32610-0322

General Clinical Research Center, Shands Hospital, University of Florida, Gainesville

All Listed Sponsors
collaborator

National Center for Research Resources (NCRR)

NIH

lead

University of Florida

OTHER

NCT00235573 - Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption | Biotech Hunter | Biotech Hunter